AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05178472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Receive SOC immunotherapy
Study NCT05178472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT05178472 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT05178472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Undergo vertebroplasty
Study NCT05900375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Decision Aid
Description: A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.
Study NCT04492449 — intervention group
Intervention type: OTHER
Intervention: congenital malformation
Description: congenital malformation
Study NCT06426212 — intervention group
Intervention type: DRUG
Intervention: Use of teicoplanin three times a week
Description: retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
Study NCT05199987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Occupational Therapy
Description: Standard occupational therapy sessions include patient therapeutic education (implementation of strategies and/or technical aids promoting autonomy and independence), walking and stair exercises in real-life conditions (weighted shopping bag, unstable ground, ...), as well as work on activities of daily living aiming to improve toileting skills (includes individual assessment, the use of technical aids depending of this assessment, and personalised strategies to conserve energy).
Study NCT05199987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy with Breathing Control Exercises
Description: Includes the same treatment than the one described in standard occupation therapy but with the addition of 30-minute sessions per day on breathing control exercises. These exercises included the reproduction of gestures reproducing daily activities and simultaneous explanations of breathing techniques that the patient can perform in order to set up strategies for saving breath during exercise.
Study NCT05116917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
Study NCT05116917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
Study NCT05116917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)
Study NCT05116917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: * A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% > 95%).
Study NCT04486118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril Pills
Description: Tablets will be taken by oral administration daily, based on titration
Study NCT04486118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benazepril Pill
Description: Tablets will be taken by oral administration daily, based on titration
Study NCT05229328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
Study NCT05691946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping
Description: The experimental group was applied 'Y shaped' kinesiology taping on gastro-soleus muscle group, based on facilitation technique with 25-50% stretching.
Study NCT05691946 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Taping
Description: The placebo group was applied kinesiology taping on gastro-soleus muscle group without any stretching.
Study NCT05161221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
Study NCT05161221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: Participant will receive Naproxen 500 Mg post surgery for pain control
Study NCT05161221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol Pill
Description: Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
Study NCT05161221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
Study NCT05161221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Catheter
Description: Participants will receive pre-operative femoral nerve catheter
Study NCT05684263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Science Educational Video
Description: Educational videos on the topic of weight science created by a registered clinical psychologist.
Study NCT05684263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Weight Science Educational Video
Description: Educational videos on the topic of weight science created by a registered clinical psychologist.
Study NCT05684263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Eating Educational Video
Description: Educational videos on the topic of healthy eating created by a registered clinical psychologist.
Study NCT05684263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Eating Educational Video
Description: Educational videos on the topic of healthy eating created by a registered clinical psychologist.
Study NCT05684263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Sleep Educational Video
Description: Educational videos on the topic of healthy sleep created by a registered clinical psychologist.
Study NCT06208449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic repair for EA
Description: The paitents with EA were repaired by Da Vinci robot
Study NCT06208449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair for EA
Description: The patients with EA were repaired by thoracoscopy
Study NCT06208449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy repair for EA
Description: The patients with EA were repaired by traditional open thoracotomy.
Study NCT05113745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-12 (reboxetine)
Description: AXS-12 tablets, taken twice daily
Study NCT05113745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study NCT05981742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG
Description: Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
Study NCT05981742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline 0.5 MG
Description: Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
Study NCT05981742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG
Description: Metformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration~Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
Study NCT04438525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: sting challenge
Description: At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
Study NCT04438525 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood donation
Description: To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
Study NCT05179304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oncoplastic technique with a droplet-shaped glandular flap
Description: A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps.
Study NCT05246657 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-guided Entero-biliary Anastomosis
Description: EUS-guided Entero-biliary Anastomosis
Study NCT04808752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
Study NCT04970212 — intervention group
Intervention type: DEVICE
Intervention: BioTraceIO Lite
Description: The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
Study NCT05471011 — intervention group
Intervention type: OTHER
Intervention: Blood and nasal swab sampling
Description: Blood and nasal swab sampling
Study NCT06106230 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bee venom phonophoresis
Description: Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products \& Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
Study NCT06106230 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Bee venom phonophoresis
Description: Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products \& Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
Study NCT04790695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
Study NCT05683106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom silicone digital orthosis (CSDO)
Description: Custom silicone digital orthosis (CSDO) will be made under mold to provide realignment of toes, protection or replacement of a segment that was amputated.They will be indicated for corrections of rigid/fixed or flexible toes deformities.CSDO will be constructed using different types of silicone and different hardness considering whether the deformities are rigid or flexible and,when necessary,these components of the orthoses will be merged.Intervention participants will be asked to clean the CSDO and interdigital spaces with soap and water;adequate drying of the fingers and interdigital region;always wear the CSDO with appropriate footwear and socks;keep monitoring the integrity of the CSDO and always communicate any identification of changes in the feet or CSDO.Adverse effects will be evaluated, such as:possible skin irritation; discomfort or pain;contractures;trauma due to friction.Adherence will be verified every 3 months and via telephone contact,monthly.
Study NCT05726435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soluble dietary fiber with prebiotic properties
Description: 14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. The Nutriose group in this particular intervention contains 7 randomy selected players.
Study NCT05726435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions.
Study NCT04935203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take \~2 min.
Study NCT06321822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES)
Description: Patient selected for genetic study will undergo blood sample collection for DNA estraction, biobank storage and WES study
Study NCT05701709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
Study NCT05684848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol + CMG
Description: As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
Study NCT05684848 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic solution
Description: As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
Study NCT04214587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: tissue and blood sampling
Description: only diagnostics will be peformed
Study NCT05985746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality group
Description: * Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience.
Study NCT05985746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional learning group
Description: * Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience.
Study NCT05557175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
Study NCT05557175 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
Study NCT05064527 — intervention group
Intervention type: DEVICE
Intervention: wearable biosensor
Description: The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
Study NCT05064527 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treatment as usual (TAU)
Description: Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
Study NCT05064527 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure and response prevention (ERP)
Description: One ERP session will be offered in Week 0 and Week 8.
Study NCT04799743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
Study NCT04799743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Study NCT04476251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 T-Cell Receptor (TCR)
Description: Patients will receive up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).